Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases*

The receptor for advanced glycation end products (RAGE) is a 55-kDa type I membrane glycoprotein of the immunoglobulin superfamily. Ligand-induced up-regulation of RAGE is involved in various pathophysiological processes, including late diabetic complications and Alzheimer disease. Application of recombinant soluble RAGE has been shown to block RAGE-mediated pathophysiological conditions. After expression of full-length RAGE in HEK cells we identified a 48-kDa soluble RAGE form (sRAGE) in the culture medium. This variant of RAGE is smaller than a 51-kDa soluble version derived from alternative splicing. The release of sRAGE can be induced by the phorbol ester PMA and the calcium ionophore calcimycin via calcium-dependent protein kinase C subtypes. Hydroxamic acid-based metalloproteinase inhibitors block the release of sRAGE, and by RNA interference experiments we identified ADAM10 and MMP9 to be involved in RAGE shedding. In protein biotinylation experiments we show that membrane-anchored full-length RAGE is the precursor of sRAGE and that sRAGE is efficiently released from the cell surface. We identified cleavage of RAGE to occur close to the cell membrane. Ectodomain shedding of RAGE simultaneously generates sRAGE and a membrane-anchored C-terminal RAGE fragment (RAGE-CTF). The amount of RAGE-CTF increases when RAGE-expressing cells are treated with a γ-secretase inhibitor, suggesting that RAGE-CTF is normally further processed by γ-secretase. Identification of these novel mechanisms involved in regulating the availability of cell surface-located RAGE and its soluble ectodomain may influence further research in RAGE-mediated processes in cell biology and pathophysiology.

[1]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  C. Heizmann,et al.  Calcium-regulated intramembrane proteolysis of the RAGE receptor. , 2008, Biochemical and biophysical research communications.

[3]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  D. Hartmann,et al.  Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17 , 2008 .

[5]  N. Kaminski,et al.  A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. , 2008, The American journal of pathology.

[6]  P. Nawroth,et al.  Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. , 2007, Cardiovascular diabetology.

[7]  D. Stern,et al.  RAGE in inflammation: a new therapeutic target? , 2006, Current opinion in investigational drugs.

[8]  K. Tsuneyama,et al.  Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. , 2006, The Biochemical journal.

[9]  A. Schmidt,et al.  RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. , 2006, Atherosclerosis.

[10]  E. Kojro,et al.  The neuropeptide PACAP promotes ?‐secretase pathway for processing Alzheimer amyloid precursor protein , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  A. D'Angelo,et al.  Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. , 2005, Archives of neurology.

[12]  A. D'Angelo,et al.  Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.

[13]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[14]  M. Pelto-huikko,et al.  Shedding light on ADAM metalloproteinases. , 2005, Trends in biochemical sciences.

[15]  N. Ozaki,et al.  RasGRP3 mediates phorbol ester-induced, protein kinase C-independent exocytosis. , 2005, Biochemical and biophysical research communications.

[16]  J. Keller,et al.  Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain , 2004, Neuroscience Letters.

[17]  J. Enghild,et al.  Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)* , 2004, Journal of Biological Chemistry.

[18]  Jeon-Soo Shin,et al.  Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.

[19]  P. Rogalla,et al.  Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.

[20]  G. Taraboletti,et al.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.

[21]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[22]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[23]  J. Arribas,et al.  Protein ectodomain shedding. , 2002, Chemical reviews.

[24]  Pedro Romero,et al.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.

[25]  A. Schmidt,et al.  RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.

[26]  L. Matrisian,et al.  Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.

[27]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[28]  G. Struhl,et al.  Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. , 2000, Molecular cell.

[29]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[30]  P. Malherbe,et al.  cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.

[31]  N. Hooper,et al.  Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells. , 1999, Biochemistry.

[32]  M. Racchi,et al.  Activity of α‐Secretase as the Common Final Effector of Protein Kinase C‐Dependent and ‐Independent Modulation of Amyloid Precursor Protein Metabolism , 1999, Journal of neurochemistry.

[33]  I. Stamenkovic,et al.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.

[34]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[35]  B. Zlokovic,et al.  Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. , 1998, The Journal of clinical investigation.

[36]  A. Schmidt,et al.  Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. , 1997, Molecular pharmacology.

[37]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[38]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[39]  A. Eisen,et al.  Human skin fibroblast procollagenase: mechanisms of activation by organomercurials and trypsin. , 1983, Biochemistry.